Literature DB >> 15816831

Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA.

Vassiliki Bekou1, Sybille Thoma-Uszynski, Olaf Wendler, Wolfgang Uter, Susanne Schwietzke, Thomas Hunziker, Christos C Zouboulis, Gerold Schuler, Lydia Sorokin, Michael Hertl.   

Abstract

Mucous membrane pemphigoid (MMP) is an autoimmune bullous disease that primarily affects mucous membranes leading to a scarring phenotype. MMP patients produce auto-antibodies (auto-ab) that preferentially recognize two components of the dermoepidermal basement membrane zone (BMZ): bullous pemphigoid (BP)180 and laminin 5 (LN5). Since detection of disease-specific auto-ab may be critical for diagnosis of MMP, we developed an ELISA with affinity-purified native human LN5. A total of 24 MMP, 72 BP, and 51 control sera were analyzed for LN5-specific auto-ab: 18/24 (75.0%) MMP and 29/72 (40.3%) BP sera were LN5 reactive. Sensitivity and specificity of the LN5 ELISA for MMP were 75% and 84.3%, respectively, and 40.3% and 88.2% for BP, respectively. The LN5 ELISA was more sensitive than a dot blot assay with native LN5, which detected LN5-reactive IgG in 14/24 (58.3%) MMP and 16/72 (22.2%) BP sera. In MMP, but not BP, levels of LN5-reactive IgG correlated with disease severity. Furthermore, IgG reactivity to LN5 of the MMP and BP sera was not significantly associated with IgG reactivity against other autoantigens of the BMZ, such as BP180 or BP230. Thus, the established LN5 ELISA holds great promise as a novel diagnostic and prognostic parameter for MMP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816831     DOI: 10.1111/j.0022-202X.2005.23646.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  12 in total

1.  Diagnosis and clinical severity markers of bullous pemphigoid.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  F1000 Med Rep       Date:  2009-02-24

2.  [Diagnostic use of autoantibodies].

Authors:  C Günther; M Hertl; M Meurer
Journal:  Hautarzt       Date:  2007-12       Impact factor: 0.751

3.  IgG anti-laminin-332 autoantibodies are present in a subset of patients with mucous membrane, but not bullous, pemphigoid.

Authors:  Zelmira Lazarova; Valerie K Salato; Christoph M Lanschuetzer; Marleen Janson; Janet A Fairley; Kim B Yancey
Journal:  J Am Acad Dermatol       Date:  2008-04-08       Impact factor: 11.527

Review 4.  Eosinophils in Autoimmune Diseases.

Authors:  Nicola L Diny; Noel R Rose; Daniela Čiháková
Journal:  Front Immunol       Date:  2017-04-27       Impact factor: 7.561

5.  Molecular diagnosis of anti-laminin 332 (epiligrin) mucous membrane pemphigoid.

Authors:  Roxana Chiorean; Sorina Danescu; Oana Virtic; Mayson B Mustafa; Adrian Baican; Annette Lischka; Takashi Hashimoto; Yoshinobu Kariya; Manuel Koch; Cassian Sitaru
Journal:  Orphanet J Rare Dis       Date:  2018-07-06       Impact factor: 4.123

Review 6.  Serological Diagnosis of Autoimmune Bullous Skin Diseases.

Authors:  Sandra Saschenbrecker; Ingolf Karl; Lars Komorowski; Christian Probst; Cornelia Dähnrich; Kai Fechner; Winfried Stöcker; Wolfgang Schlumberger
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

7.  Keratinocyte footprint assay discriminates antilaminin-332 pemphigoid from all other forms of pemphigoid diseases.

Authors:  F Giurdanella; A M Nijenhuis; G F H Diercks; M F Jonkman; H H Pas
Journal:  Br J Dermatol       Date:  2019-08-09       Impact factor: 9.302

Review 8.  [Mucous membrane pemphigoid with ocular involvement. Part I: Clinical manifestations, pathogenesis and diagnosis].

Authors:  E Schmidt; T Meyer-Ter-Vehn; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-03       Impact factor: 1.174

Review 9.  Diagnosis of Autoimmune Blistering Diseases.

Authors:  Mareike Witte; Detlef Zillikens; Enno Schmidt
Journal:  Front Med (Lausanne)       Date:  2018-11-02

10.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.